The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 760K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

22 articles for CA Janson


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
40
Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.EBI
Hoffmann-La Roche
23
Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain.EBI
Hoffmann-La Roche
1
Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.EBI
Smithkline Beecham Pharmaceuticals
8
Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.EBI
Smithkline Beecham Pharmaceuticals
11
Identification of an Adamantyl Azaquinolone JNK Selective Inhibitor.EBI
TBA
15
Azepanone-based inhibitors of human and rat cathepsin K.EBI
Glaxosmithkline
13
Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.EBI
Smithkline Beecham Pharmaceuticals
15
Protein structure-based design, synthesis, and biological evaluation of 5-thia-2,6-diamino-4(3H)-oxopyrimidines: potent inhibitors of glycinamide ribonucleotide transformylase with potent cell growth inhibition.EBI
Agouron Pharmaceuticals
14
Structure-based design of substituted diphenyl sulfones and sulfoxides as lipophilic inhibitors of thymidylate synthase.EBI
Agouron Pharmaceuticals
24
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.EBI
Agouron Pharmaceuticals
15
Synthesis and biological evaluation of novel 2,6-diaminobenz[cd]indole inhibitors of thymidylate synthase using the protein structure as a guide.EBI
Agouron Pharmaceuticals
14
Design of enzyme inhibitors using iterative protein crystallographic analysis.EBI
Agouron Pharmaceuticals
14
Design and synthesis of novel 6,7-imidazotetrahydroquinoline inhibitors of thymidylate synthase using iterative protein crystal structure analysis.EBI
Agouron Pharmaceuticals
41
Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)BDB
Janssen Ireland
231
Substituted tricyclic compounds as FGFR inhibitorsBDB
Incyte
43
Substituted tetrahydrocarbazole and carbazole carboxamide compoundsBDB
Bristol-Myers Squibb
48
Aniline derivative, pharmaceutical composition containing same, and use thereofBDB
Kissei Pharmaceutical
16
1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.BDB
Johnson & Johnson Pharmaceutical
46
Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase.BDB
University of Regensburg
70
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.BDB
Glaxosmithkline
35
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.BDB
Dupont Pharmaceuticals
9
Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.BDB
Dupont Pharmaceuticals